Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ADC Therapeutics ( (ADCT) ) has issued an announcement.
On June 11, 2025, ADC Therapeutics SA announced a $100 million private placement with institutional investors, selling common shares and pre-funded warrants. This strategic move is aimed at bolstering their financial position and facilitating the company’s focus on expanding ZYNLONTA® and advancing its PSMA-targeting ADC. Concurrently, the company announced a restructuring plan to streamline operations by shutting down its U.K. research facility and reducing its workforce by 30%, with expected completion by September 30, 2025. This restructuring is anticipated to incur one-time pre-tax charges of approximately $6 million to $7 million.
The most recent analyst rating on (ADCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
Spark’s Take on ADCT Stock
According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.
ADC Therapeutics’ overall stock score is primarily impacted by its weak financial performance and challenging valuation. While technical analysis shows bullish momentum, and corporate events and earnings call provide some positive insights, the company’s financial instability and negative profitability weigh heavily on the overall score.
To see Spark’s full report on ADCT stock, click here.
More about ADC Therapeutics
ADC Therapeutics SA operates in the biotechnology industry, focusing on the development of antibody-drug conjugates (ADCs) for the treatment of cancer. The company is particularly focused on expanding its ZYNLONTA® (loncastuximab tesirine-lpyl) product and advancing its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA).
Average Trading Volume: 528,135
Technical Sentiment Signal: Buy
Current Market Cap: $364M
See more data about ADCT stock on TipRanks’ Stock Analysis page.